30 Oct 2019 14:28
Result of AGM
Oxford, UK; 30 October 2019: Sensyne Health plc (LSE: SENS) ("Company"), the British clinical AI technology company, announces that all resolutions put to its Annual General Meeting (the "AGM") held today were passed. Resolution 10 was withdrawn by the Company following the decision of Charles Swingland not to seek re-election as a Director at the AGM.
For information, full details of the votes received were as follows:
Resolution Number | For | Against | Withheld | Total Vote | ||
No. of Votes | % | No. of Votes | % | No. of Votes | No. of Votes | |
1. Receive the Annual report and accounts for the Company | 83,669,303 | 100.00 | 250 | 0.00 | 7,300,000 | 83,669,553 |
2. Approve the Directors' Remuneration Report | 59,657,635 | 71.30 | 24,011,918 | 28.70 | 7,300,000 | 83,669,553 |
3. Re-elect Lord (Paul) Drayson as a Director | 49,183,591 | 100.00 | 2,000 | 0.00 | 15,270 | 49,185,591 |
4. Re-elect Andrew Gilbert as a Director | 75,420,438 | 90.16 | 8,233,865 | 9.84 | 7,315,250 | 83,654,303 |
5. Re-elect Dr Vishal Gulati as a Director | 83,654,303 | 100.00 | 0 | 0.00 | 7,315,250 | 83,654,303 |
6. Re-elect Mary Hardy as a Director | 83,654,303 | 100.00 | 0 | 0.00 | 7,315,250 | 83,654,303 |
7. Re-elect Lorimer Headley as a Director | 83,654,303 | 100.00 | 0 | 0.00 | 7,315,250 | 83,654,303 |
8. Re-elect Dr Annalisa Jenkins as a Director | 90,954,303 | 100.00 | 0 | 0.00 | 15,250 | 90,954,303 |
9. Re-elect Sir Bruce Keogh as a Director | 83,654,303 | 100.00 | 0 | 0.00 | 7,315,250 | 83,654,303 |
10. Re-elect Charles Swingland as a Director | RESOLUTION WITHDRAWN | |||||
11. Elect Professor Lionel Tarassenko as a Director | 83,497,695 | 99.81 | 156,608 | 0.19 | 7,315,250 | 83,654,303 |
12. Re-appoint PricewaterhouseCoopers LLP as auditors of the Company | 83,669,303 | 100.00 | 0 | 0.00 | 7,300,250 | 83,669,303 |
13. Authorise the Audit & Risk Committee of the Company | 83,669,303 | 100.00 | 0 | 0.00 | 7,300,250 | 83,669,303 |
14. Directors' authority to allot shares | 80,209,253 | 100.00 | 0 | 0.00 | 10,760,300 | 80,209,253 |
15. Disapplication of pre-emption rights* | 80,209,253 | 100.00 | 0 | 0.00 | 10,760,300 | 80,209,253 |
16. Disapplication of pre-emption rights Addition* | 80,206,753 | 100.00 | 0 | 0.00 | 10,762,800 | 80,206,753 |
17. Authority to purchase own shares* | 80,209,253 | 100.00 | 0 | 0.00 | 10,760,300 | 80,209,253 |
18. Rule 9 Waiver - Relating to Buyback Authority | 25,056,044 | 65.18 | 13,384,497 | 34.82 | 10,760,320 | 38,440,541 |
19. Rule 9 Waiver - Relating to the Exercise of Options | 25,053,544 | 65.17 | 13,386,997 | 34.83 | 10,760,320 | 38,440,541 |
Notes:
1. Resolution 10 was withdrawn as Charles Swingland decided not to seek re-election as a Director at the AGM.
2. A vote withheld is not a vote in law and is not counted in calculating votes for or against a resolution.
3. The total number of ordinary shares in issue as at 30 October 2019 was 128,571,514 (128,571,514 with voting rights).
* Special Resolution requiring a 75% majority.
The Board notes that more than 20% of shareholders voted against resolution 2 on approving the Directors' Remuneration Report. As noted in the Company's announcement of 22 October 2019 headed Remuneration Policy and Corporate Governance Update, a number of actions have already been implemented addressing the issue of remuneration. The Company has withdrawn the remuneration policy in relation to the CEO for the period from 1st May 2019 to 30th April 2020 and the Remuneration Committee will also undertake discussions with shareholders to determine a new Remuneration Policy for the CEO applicable to the period from 1st May 2019 until 30th April 2020 that has their support.
-ENDS-
For more information please contact:
Sensyne Health (www.sensynehealth.com) | +44 (0) 330 058 1845 |
Lord (Paul) Drayson, Chief Executive Officer | |
Lorimer Headley, Chief Financial Officer | |
Peel Hunt LLP (Nominated Adviser and Joint Broker) | + 44 (0) 20 7418 8900 |
Dr Christopher Golden | |
James Steel | |
Oliver Jackson | |
| |
Liberum (Joint Broker) | + 44 (0) 20 3100 2000 |
Bidhi Bhoma | |
Euan Brown | |
Consilium Strategic Communications | +44 20 3709 5700 |
Mary-Jane Elliott | |
Sukaina Virji | |
Melissa Gardiner | |
sensynehealth@consilium-comms.com |
About Sensyne Health
Sensyne Health plc is a healthcare technology company that creates value from accelerating the discovery and development of new medicines and improving patient care through the analysis of real-world evidence from large databases of anonymised patient data in collaboration with NHS Trusts. These anonymised patient data are ethically sourced in that any analysis of anonymised patient data (and hence the Company's access to it) must be pre-approved for each programme on a case-by-case basis by the relevant NHS Trusts. This is to ensure that the purpose of the anonymisation and the proposed analysis are subject to appropriate ethical oversight and information governance, including conformance with NHS principles, UK data protection law and applicable regulatory guidance. Sensyne Health is an early signatory to the Department of Health and Social Care's 'Initial Code of Conduct for data-driven health and care technology.
Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).
For more information, please visit: www.sensynehealth.com